Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA

Retrovirology

John M Coffin²  Robert M Stephens⁴  Alexander Levitsky⁴  Natalia Volfovsky⁴  Claudia Stewart¹  John W Mellors³  Frank Maldarelli⁵  Mary F Kearney⁵  Jonathan E Spindler⁵  Valerie F Boltz⁵  Wei Shao⁴ 

[1] LMT, SAIC Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD, USA;Tufts University, Boston, MA, USA;Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA;Advanced Biomedical Computing Center, SAIC Frederick, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, USA;HIV Drug Resistance Program, NCI, PO Box B, Frederick, MD, USA

关键词: PCR induced recombination;    Error rate;    HIV-1;    454 pyrosequencing;   

Others  :  1209163
DOI  :  10.1186/1742-4690-10-18

 received in 2012-07-18, accepted in 2013-02-01,  发布年份 2013

【 摘 要 】

Background

454 sequencing technology is a promising approach for characterizing HIV-1 populations and for identifying low frequency mutations. The utility of 454 technology for determining allele frequencies and linkage associations in HIV infected individuals has not been extensively investigated. We evaluated the performance of 454 sequencing for characterizing HIV populations with defined allele frequencies.

Results

We constructed two HIV-1 RT clones. Clone A was a wild type sequence. Clone B was identical to clone A except it contained 13 introduced drug resistant mutations. The clones were mixed at ratios ranging from 1% to 50% and were amplified by standard PCR conditions and by PCR conditions aimed at reducing PCR-based recombination. The products were sequenced using 454 pyrosequencing. Sequence analysis from standard PCR amplification revealed that 14% of all sequencing reads from a sample with a 50:50 mixture of wild type and mutant DNA were recombinants. The majority of the recombinants were the result of a single crossover event which can happen during PCR when the DNA polymerase terminates synthesis prematurely. The incompletely extended template then competes for primer sites in subsequent rounds of PCR. Although less often, a spectrum of other distinct crossover patterns was also detected. In addition, we observed point mutation errors ranging from 0.01% to 1.0% per base as well as indel (insertion and deletion) errors ranging from 0.02% to nearly 50%. The point errors (single nucleotide substitution errors) were mainly introduced during PCR while indels were the result of pyrosequencing. We then used new PCR conditions designed to reduce PCR-based recombination. Using these new conditions, the frequency of recombination was reduced 27-fold. The new conditions had no effect on point mutation errors. We found that 454 pyrosequencing was capable of identifying minority HIV-1 mutations at frequencies down to 0.1% at some nucleotide positions.

Conclusion

Standard PCR amplification results in a high frequency of PCR-introduced recombination precluding its use for linkage analysis of HIV populations using 454 pyrosequencing. We designed a new PCR protocol that resulted in a much lower recombination frequency and provided a powerful technique for linkage analysis and haplotype determination in HIV-1 populations. Our analyses of 454 sequencing results also demonstrated that at some specific HIV-1 drug resistant sites, mutations can reliably be detected at frequencies down to 0.1%.

【 授权许可】

   
2013 Shao et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ronaghi M, Shokralla S, Gharizadeh B: Pyrosequencing for discovery and analysis of DNA sequence variations. Pharmacogenomics 2007, 8:1437-1441.
• [2]Rothberg JM, Leamon JH: The development and impact of 454 sequencing. Nat Biotechnol 2008, 26:1117-1124.
• [3]Bushman FD, Hoffmann C, Ronen K, Malani N, Minkah N, Rose HM, Tebas P, Wang GP: Massively parallel pyrosequencing in HIV research. AIDS 2008, 22:1411-1415.
• [4]Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, Gharizadeh B, Ronaghi M, Shafer RW, Beerenwinkel N: Viral population estimation using pyrosequencing. PLoS Comput Biol 2008, 4:e1000074.
• [5]Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ: Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009, 4:e6079.
• [6]Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW: Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 2008, 82:10747-10755.
• [7]O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J: Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol 2001, 39:464-473.
• [8]Poon AF, Swenson LC, Dong WW, Deng W, Kosakovsky Pond SL, Brumme ZL, Mullins JI, Richman DD, Harrigan PR, Frost SD: Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol 2010, 27:819-832.
• [9]Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR: Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. AIDS 2009, 23:2541-2543.
• [10]Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR: Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15. BioMed Central Full Text
• [11]Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009, 199:693-701.
• [12]Valerie Boltz YZ, Lockman S, Hong F, Halvas E, McIntyre J, Currier J, Hughes M, Coffin J, Mellors J: Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 2011, 108(22):9202-9207.
• [13]Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM: Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 2007, 8:R143. BioMed Central Full Text
• [14]Meyerhans A, Vartanian JP, Wain-Hobson S: DNA recombination during PCR. Nucleic Acids Res 1990, 18:1687-1691.
• [15]Judo MS, Wedel AB, Wilson C: Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res 1998, 26:1819-1825.
• [16]Beser J, Hagblom P, Fernandez V: Frequent in vitro recombination in internal transcribed spacers 1 and 2 during genotyping of Pneumocystis jirovecii. J Clin Microbiol 2007, 45:881-886.
• [17]von Wintzingerode F, Gobel UB, Stackebrandt E: Determination of microbial diversity in environmental samples: pitfalls of PCR-based rRNA analysis. FEMS Microbiol Rev 1997, 21:213-229.
• [18]Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW: Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007, 17:1195-1201.
• [19]Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E: The impact of PCR-generated recombination on diversity estimation of mixed viral populations by deep sequencing. J Virol Methods 2010, 169:248-252.
• [20]Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, Methe B, DeSantis TZ, Petrosino JF, Knight R, Birren BW: Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 2011, 21:494-504.
• [21]Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J: Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 2010, 5:e11345.
• [22]Mild M, Hedskog C, Jernberg J, Albert J: Performance of ultra-deep pyrosequencing in analysis of HIV-1 pol gene variation. PLoS One 2011, 6:e22741.
• [23]Quince C, Lanzen A, Davenport RJ, Turnbaugh PJ: Removing noise from pyrosequenced amplicons. BMC Bioinforma 2011, 12:38. BioMed Central Full Text
• [24]Vandenbroucke I, Van Marck H, Verhasselt P, Thys K, Mostmans W, Dumont S, Van Eygen V, Coen K, Tuefferd M, Aerssens J: Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011, 51:167-177.
• [25]Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen YJ, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen S, Ho CH, Irzyk GP, Jando SC, Alenquer ML, Jarvie TP, Jirage KB, Kim JB, Knight JR, Lanza JR, Leamon JH, Lefkowitz SM, Lei M, Li J, Lohman KL, Lu H, Makhijani VB, McDade KE, McKenna MP, Myers EW, Nickerson E, Nobile JR, Plant R, Puc BP, Ronan MT, Roth GT, Sarkis GJ, Simons JF, Simpson JW, Srinivasan M, Tartaro KR, Tomasz A, Vogt KA, Volkmer GA, Wang SH, Wang Y, Weiner MP, Yu P, Begley RF, Rothberg JM: Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380.
• [26]Gilbert MT, Binladen J, Miller W, Wiuf C, Willerslev E, Poinar H, Carlson JE, Leebens-Mack JH, Schuster SC: Recharacterization of ancient DNA miscoding lesions: insights in the era of sequencing-by-synthesis. Nucleic Acids Res 2007, 35:1-10.
• [27]Wicker T, Schlagenhauf E, Graner A, Close TJ, Keller B, Stein N: 454 sequencing put to the test using the complex genome of barley. BMC Genomics 2006, 7:275. BioMed Central Full Text
• [28]Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR: Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009, 4:e5683.
• [29]Boyer PL, Sarafianos SG, Arnold E, Hughes SH: Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001, 75:4832-4842.
• [30]Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, Martin JF: Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 2011, 12:245. BioMed Central Full Text
• [31]Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Mellors JW, Coffin JM: Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006, 20:701-710.
• [32]Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R: Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 2011, 108:20166-20171.